APIC Publishes New Industry Best Practices Documents - Pharmaceutical Technology

Latest Issue
PharmTech

Latest Issue
PharmTech Europe

APIC Publishes New Industry Best Practices Documents


The Active Pharmaceutical Ingredients Committee (APIC) has published two new documents: Guidance on aspects of cleaning validation in active pharmaceutical ingredients plants and GDP for APIs: “How to do” Document.

Guidance on aspects of cleaning validation in active pharmaceutical ingredients plants: This document is an update of the original guidance on cleaning validation in API manufacturing plants and reflects the outcome of discussions between APIC member companies on how cleaning validation requirements could be fulfilled and implemented as part of routine operations. APIC is also aligning this guidance with the ISPE Risk MaPP Guide that follows the quality risk management processes as described in the ICH Q9 Guidance on Quality Risk Management.
The purpose of this document is to assist companies in the formulation of cleaning validation programs and includes examples of how member companies have dealt with specific areas and issues that arise when performing cleaning validation. It provides a starting point for internal discussions and should not be considered as a technical standard. The topics addressed in this guidance document include acceptance criteria, levels of cleaning, control of the cleaning process, bracketing and worst case rating, determination of the amount of residue, and cleaning validation protocol.
GDP for APIs: “How to do” Document: With the application of GDP for APIs becoming mandatory under the EU Falsified Medicines Directive (Directive 2011/62/EU), this document provides guidance, based on practical experience, on how to implement the Guidelines on the Principles of Active Substances for Medicinal Products for Human Use draft published by the European Commission DG SANCO.
Source: APIC

ADVERTISEMENT

blog comments powered by Disqus
LCGC E-mail Newsletters

Subscribe: Click to learn more about the newsletter
| Weekly
| Monthly
|Monthly
| Weekly

Survey
FDASIA was signed into law two years ago. Where has the most progress been made in implementation?
Reducing drug shortages
Breakthrough designations
Protecting the supply chain
Expedited reviews of drug submissions
More stakeholder involvement
Reducing drug shortages
70%
Breakthrough designations
4%
Protecting the supply chain
17%
Expedited reviews of drug submissions
2%
More stakeholder involvement
7%
View Results
Eric Langerr Outsourcing Outlook Eric LangerTargeting Different Off-Shore Destinations
Cynthia Challener, PhD Ingredients Insider Cynthia ChallenerAsymmetric Synthesis Continues to Advance
Jill Wechsler Regulatory Watch Jill Wechsler Data Integrity Key to GMP Compliance
Sean Milmo European Regulatory WatchSean MilmoExtending the Scope of Pharmacovigilance Comes at a Price
From Generics to Supergenerics
CMOs and the Track-and-Trace Race: Are You Engaged Yet?
Ebola Outbreak Raises Ethical Issues
Better Comms Means a Fitter Future for Pharma, Part 2: Realizing the Benefits of Unified Communications
Better Comms Means a Fitter Future for Pharma, Part 1: Challenges and Changes

Click here